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Abstract
Background: Directly observed therapy (DOT) remains the cornerstone of the global tuberculosis (TB) control
strategy. Tanzania, one of the 22 high-burden countries regarding TB, changed the first-line treatment regimen to contain
rifampicin-containing fixed-dose combination for the full 6 months of treatment. As daily health facility-based DOT for
this long period is not feasible for the patient, nor for the health system, Tanzania introduced patient centred treatment
(PCT). PCT allows patients to choose for daily DOT at a health facility or at their home by a supporter of choice. The
introduction of fixed dose combinations in the intensive and continuation phase made PCT feasible by eliminating the
risk of selective drug taking by patients and reducing the number of tablets to be taken. The approach was tested in three
districts with the objective to assess the effect of this strategy on TB treatment outcomes
Methods: Cohort analysis comparing patients treated under the PCT strategy (registered April-September 2006) with
patients treated under health-facility-based DOT (registered April-September 2005). The primary outcome was the cure
rate. Differences were assessed by calculating the risk ratios. Associations between characteristics of the supporters and
treatment outcomes in the group of patients opting for home-based DOT were assessed through logistic regression.
Results: In the PCT cohort there were 1208 patients and 1417 were included in the historic cohort. There was no
significant difference in cure rates between the cohorts (risk ratio [RR]: 1.06; 95% confidence interval [CI]: 0.96-1.16).
In the PCT cohort, significantly more patients had successful treatment (cure or treatment completed; RR: 1.10; 95%CI:
1.01-1.15). There were no characteristics of supporters that were associated with treatment outcome.
Conclusion: The PCT approach showed similar cure rates and better treatment success rates compared to daily health-
facility DOT. The results indicate that there are no specific prerequisites for the supporter chosen by the patient. The
programmatic setting of the study lends strong support for scaling-up of TB treatment observation outside the health
facility.
Published: 21 December 2009
BMC Medicine 2009, 7:80 doi:10.1186/1741-7015-7-80
Received: 19 November 2009
Accepted: 21 December 2009
This article is available from: http://www.biomedcentral.com/1741-7015/7/80
© 2009 Egwaga et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 10
(page number not for citation purposes)
BMC Medicine 2009, 7:80 http://www.biomedcentral.com/1741-7015/7/80Background
Tanzania is one of the 22 high-burden countries with
respect to the number of incident tuberculosis (TB)
cases[1]. Up to the mid-eighties of the previous century,
the annual number of cases identified and treated in the
country was manageable, but due to the developing epi-
demic with the human immunodeficiency virus (HIV),
the caseload in Tanzania increased rapidly. Within 5
years, the number of TB cases notified tripled from 5000
to 15,000 between 1980 and 1985. In 2006, Tanzania
reported over 62,000 TB cases (157 cases per 100,000
population), while the World Health Organization
(WHO) estimated the incidence to be 312 per 100,000
population [1]. Thirty-five percent of smear-positive TB
patients were HIV-positive in a recent study [2].
The currently recommended strategy for TB control is the
directly observed treatment, short course (DOTS) [3,4].
This strategy includes, amongst others, the daily observa-
tion of patients' drug intake at the treating facility during
the initial 2 months of therapy. The reason behind this
observation is that it will ensure adequate treatment
adherence during the period, in which the treatment regi-
men contains rifampicin which will prevent the selection
of Mycobacterium tuberculosis strains resistant to this pow-
erful drug [5-8].
The National Tuberculosis and Leprosy Programme
(NTLP) of Tanzania changed the standard first-line treat-
ment regimen in 2006 from an 8-month regimen to a 6-
month regimen. In the latter, both the intensive phase
treatment and the continuation phase treatment contains
rifampicin, while in the former rifampicin is only given
for 2 months of the intensive phase. The rifampicin-con-
taining regimen throughout the course of treatment has a
higher efficacy in situations with a high prevalence of
HIV-infection in the general population [9-11]. The WHO
recommends the observation of treatment throughout the
6 months of this regimen at least three times a week [3].
This is clearly not feasible at the health facility level for
either the patient or the health staff. Initial studies in
urban and rural areas of Tanzania showed that decentral-
ized treatment observation by guardians or former TB
patients was feasible without a detrimental effect on treat-
ment outcome [12,13]. The main drawback encountered
in a possible scale-up of this approach was the need for
incentives expressed by the supporters which made the
strategy non-sustainable. The experiences from these stud-
ies formed the basis of a new approach to the implemen-
tation of DOTS in Tanzania in which the observation of
treatment intake could be transferred from the health
facility to the patient's home and the observer could be
changed from a health-care worker to a supporter of
choice.
These changes maintain the core principle of daily obser-
vation of treatment (DOT) for the full duration of treat-
ment, prevent health facilities from being overburdened
and enable the patients to choose a supervision model
within the constraints of their daily life. This should have
a positive effect on treatment adherence and, subse-
quently, the efficacy of treatment. The new strategy was
labelled 'patient centred treatment' (PCT).
From previous studies it is known that DOT outside the
health facility, by either health personnel or laymen, is
feasible and can result in treatment outcomes that are sim-
ilar to those under conventional DOT at the health facility
[14-18]. In Nepal, both DOT at the health facility and
DOT by family members obtained success rates that met
the international target of 85% [17]. However, most of
these studies have been designed as randomized clinical
trials and/or put restrictions on the type of supporter who
can observe treatment intake. Clinical trials have the
inherent limitation of coming with increased supervision
and monitoring which can have a positive effect of its own
on treatment delivery and adherence. Restrictions on sup-
porters complicate the interpretation and replication of
results within the context of national control programmes
with a wider choice of potential treatment supporters.
Thus, there is an urgent need to test the concept of dele-
gating treatment observation outside the health facility
under routine programmatic conditions. This need also
holds true for fields outside the context of TB where strat-
egies other than health facility-based treatment delivery
are being examined, such as home-base care programmes
for the delivery of antiretroviral therapy to HIV-infected
patients.
The concept of PCT was tested and well perceived by
patients and health care professionals when assessed in a
qualitative survey. Furthermore, the proposed strategy
was seen to be a positive contribution to adherence to
therapy [2]. The strategy was formally tested in three dis-
tricts under programmatic conditions with no restriction
on the choice of treatment supporter. The objective of this
study was to assess whether favourable treatment out-
comes (cure and success) in new patients (that is, those
without previous TB treatment) treated under the new
strategy were no lower than those in new patients who
were treated under the conventional strategy. If so, this
would lend strong support to the practice of observing




Initially, the study was designed as a cohort study compar-
ing treatment outcomes for patients who chose home-
based treatment with those who chose health facility-Page 2 of 10
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from a community assessment in which patients, if given
a choice, were asked what would be their preference for
the place of treatment. In this assessment, just over 50%
would have opted for home-based treatment [2]. During
the implementation of the current study it became clear
that a much higher proportion of patients opted for
home-based treatment, making a formal comparison of
treatment outcomes with patients opting for health facil-
ity-based treatment statistically more difficult.
The study design was changed into a comparison of treat-
ment outcomes for patients in the PCT cohort with those
in a control cohort of all registered new TB patients in the
same facilities during the same period of time a year ear-
lier. This also changed the intervention being tested
because three variables in the PCT cohort were different
from the control cohort; the possibility of having home-
based treatment observation, treatment with fixed dose
combinations (FDCs) and a regimen with rifampicin for
the continuation phase resulting in 6 months duration
instead of 8 months. Possible differences between the
cohorts should, therefore, be attributed to the overall
intervention of PCT, rather than only the home-based set-
ting of treatment observation.
Study population and setting
The study was carried out in the Arusha Municipality, the
Kahama district (Shinyanga province) and the Mufindi
district (Iringa province) of Tanzania. The decision to
choose these sites was based on the number of notified
smear-positive TB-patients and their representativeness
for urban and rural settings in the country. Within each
area, all TB treatment facilities implemented PCT for all
new patients who were registered in the second and third
quarter of 2006. The only inclusion criterion used was
that the patient was defined as 'new', indicating that he/
she had never received any TB-treatment that lasted longer
than 1 month. The control cohort comprised all new
patients in the same health facilities registered in the sec-
ond and third quarter of 2005 who were treated under the
conventional DOTS strategy. Smear-positive TB was
recorded when two out of three sputum samples (spot,
morning, spot) were Ziehl-Neelsen positive. When clini-
cal symptoms were suggestive of TB, but sputum samples
were negative, a suggestive chest X-ray could lead to the
diagnosis of smear-negative TB.
Intervention
The intervention tested was PCT, which consisted of three
components. First, each patient was given the choice to
receive treatment at home observed by a supporter of his/
her choice or to receive daily treatment at the health facil-
ity observed by health staff. There were no restrictions on
the choice of supporter. Second, treatment for all patients
was delivered as a FDC rather than the conventional sep-
arate tables for each drug. Third, the treatment contained
isoniazid, rifampicin, ethambutol and pyrazinamide in
the initial phase of 2 months and isoniazid and
rifampicin in the continuation phase of 4 months. At any
time, patients were allowed to change from home-based
treatment to health facility-based treatment or vice versa.
There were no interventions related to default tracing and
monitoring in the PCT strategy, other than the routine
guidelines from the NTLP, making the control cohort and
the PCT cohort comparable in this respect.
Follow-up and data collection
If the patient opted for home-based treatment, he/she was
asked to return with the supporter of his choice. The sup-
porter was given instruction by the health care provider on
the importance of daily supervision of drug intake, the
signs and symptoms of side-effects, and what to do if they
occur, and the frequency of the collection of new drugs.
Supporters needed to escort the patient to the health facil-
ity on a weekly basis in the first 2 months of treatment to
collect new drugs, report on the well-being of the patient
and to discuss any problem encountered in the support of
the patient. The patient was requested to join the sup-
porter at every visit unless too ill to do so. In the remain-
ing 4 months, the visits to the health facility took place
twice a month.
Data on the demographics of patients and supporters,
drug intake, side effects and laboratory results in the PCT
cohort were prospectively recorded in specifically
designed registers and cards. Patient and laboratory data
in the control cohort were retrospectively retrieved from
the TB registers and the patient's treatment cards in the
participating health facilities. These routine registers were
checked for accuracy (and updated if needed) by the same
independent team that collected data in the PCT cohort in
order to minimize ascertainment bias. Data collection for
both cohorts took place in three rounds from September
2006 to July 2007. Follow-up ended when the last
included patient reached the time of treatment comple-
tion (April 2007). This meant that the last data collection
took place after the treatment outcome of all patients had
been recorded.
Outcome measures and explanatory variables
The primary study outcome was the proportion of new
smear-positive patients cured at the end of treatment (6
months in the PCT cohort and 8 months in the control
cohort). Secondary outcomes were the proportion of
patients with treatment success (cured or treatment com-
pleted) at 6 months or 8 months, and the proportion of
smear-positive patients with smear conversion at 2
months. In addition, we assessed whether the characteris-
tics of the treatment supporters were associated with treat-Page 3 of 10
(page number not for citation purposes)
BMC Medicine 2009, 7:80 http://www.biomedcentral.com/1741-7015/7/80ment outcomes in the group of patients with home-based
treatment observation. Cure was defined as a smear-posi-
tive patient having a negative sputum smear at the end of
treatment and on at least one previous occasion. Treat-
ment completion was defined as a patient having com-
pleted treatment but not having a final smear
examination. The characteristics of the supporters were
categorized based on distribution with the purpose of get-
ting groups of similar size. Age in years was defined as
<25, 25-34, 35-44 and ≥45. The relationship with the
patient was categorized as 'family member' or 'non family
member'. Education was categorized as 'none', 'primary'
and 'above primary'. The initially collected variable
'household of supporter' was not used due to the strong
collinearity with the variable 'relationship' in the analyses.
Quality control
All sputum smears during diagnosis and follow-up were
confirmed by an independent laboratory technician. Dis-
crepancies between the initial test and the re-reading were
resolved by a third reader whose results were final.
Statistical analyses
Baseline characteristics of the two cohorts were compared
using the χ2 test for binary variables and Student's t-test for
continuous variables. Outcome measures in the cohorts
were compared by calculating the risk ratio (RR) stratified
by district. A combined analysis of all three districts was
only performed when there was no effect modification by
district as assessed by the Cochran-Mantel-Haenszel test.
Supporter characteristics associated with cure and treat-
ment success in the group of patients with home-based
treatment observation were assessed by univariable and
multivariable logistic regression. All multivariable analy-
ses included, apart from 'place of treatment' the variable
'district' to incorporate the stratified design in the analy-
ses. Other variables were only included if they were signif-
icantly associated with the outcome in univariable
analyses with a P-value of 0.1 or less. Effect modification
by districts in these models was assessed by testing for
interactions (multiplicative). Effect modification was
assumed statistically significant at the 10% level.
Missing data and loss to follow-up
Due to an unforeseen logistical problem, the cards
designed for recording information on the supporters
were not available for the first 205 patients. Unfortu-
nately, not all information could be retrieved at a later
stage. This did not introduce a bias as the study started in
all the three districts at the same time. Furthermore, the
patients' freedom of choice for the type of treatment deliv-
ery strategy remained. The missing cards only reduced the
power of the study for the analyses assessing the effects of
supporter characteristics on treatment outcomes in the
PCT cohort.
The missing data were categorized as a separate level in
the respective variables in order to include all treatment
outcomes in the analyses. Therefore, statistical significant
associations were assessed on level the Wald test in the
logistic regression models rather than the likelihood ratio
test.
Sample size
Based on the total number of new smear-positive patients
who opted for home-based treatment and the correspond-
ing number of patients a year earlier, the power of the
study for the primary outcome was an 80% ability to
detect a statistically significant difference (α = 5%) of
8.5% when cure in the control cohort was estimated at
70%.
Ethics statement
The study was approved by the Institutional Review Board
of the Ifakara Health Institute in Tanzania. Informed con-
sent was not obtained from the participants as the inter-
vention was based on a change in national treatment
guidelines that was applied to all.
Role of the funding source
The funder of the study was involved in the study design
and data interpretation. Data collection and data analysis
were performed independently of the funder. The corre-
sponding author had access to all data in the study. The
final decision to submit for publication was made by the
NTLP of Tanzania.
Results
The study included 1208 new patients in the PCT cohort
and 1417 in the control cohort. Of these, 548 (38.7%)
and 484 (40.1%) were smear-positive (Figure 1). The pro-
portion of females and the age of the patients were com-
parable in both cohorts (Table 1). The relative
contribution of the districts for both cohorts differed:
there were slightly more patients from the urban setting in
the PCT cohort (40%) than in the control cohort (30%).
Smear-negative patients were slightly under-represented
in the PCT cohort compared to the control cohort. None
of the analyses showed an interaction by district. There-
fore, the outcomes were pooled and analysed for the total
study population.
Comparing treatment outcomes between cohorts
Treatment outcomes comparing both cohorts are summa-
rized in Table 2.
Smear-positive patients
None of the smear-positive patients in the PCT cohort
who had a smear examination at the end of treatment had
a positive smear result at the end of treatment, compared
to two in the control cohort. This implies that differences
in cure rate were driven by the presence of a smear resultPage 4 of 10
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ment. There was no statistically significant difference in
the primary outcome (cure) comparing the PCT (64.5%)
cohort with the control cohort (60.9%; RR: 1.06; 95%
confidence interval [CI]: 0.96-1.16; P = 0.136).
Smear-positive patients in the PCT cohort were more
likely to have successful treatment (82.2%) than patients
in the control cohort (69.7%; RR: 1.18; 95% CI: 1.10-
1.26; P < 0.001). This was because more patients in the
PCT cohort, compared to the historical cohort, completed
treatment and had a final smear examination performed
at the end of treatment (necessary in order to confirm
cure).
Significantly more smear-positive patients in the PCT
cohort had a recorded smear conversion at 2 months
(80.2%), than in the control cohort (74.6%; RR: 1.07;
95% CI: 1.01-1.15; P = 0.021). This difference was driven
by the fact that a larger proportion of patients in the con-
trol cohort (20.1%) died, transferred, defaulted or did not
have a sputum smear performed compared to the PCT
cohort (15.5%). Comparing the proportion of patients
with smear conversion only for those patients who were
present at month 2, and had had a smear examination,
did not reveal statistically significant changes between the
PCT cohort (93.4%) and the historic cohort (94.9%; P =
0.359).
All new patients
A comparison of the treatment outcomes for all new
patients included in the two cohorts showed a similar
finding of a higher success rate in the PCT cohort (79%)
compared to the control cohort (71.6%); RR: 1.10; 95%
CI: 1.05-1.15; P < 0.001).
Comparing treatment delivery strategies in the PCT cohort
New smear-positive patients who opted for home-based
treatment observation were more likely to be cured com-
Patient dispositionFigure 1
Patient disposition. * No information of relationship of treatment supporter for 205 patients.





































Table 1: Baseline characteristics of tuberculosis (TB) patients.
Historic PCT P-value
n = 1417* n = 1208*
District <0.001
Arusha 394 (27.8) 495 (41.0)
Kahama 394 (27.8) 329 (27.2)
Mfindi 629 (44.4) 384 (31.8)
Female 667 (47.1) 563 (41.9) 0.812
Age group
<25 292(20.6) 241 (20.0) 0.796
25-34 471 (33.2) 390(32.3)
35-44 323(22.8) 260(21.5)
>= 45 323(22.8) 290(24.0)
Missing 8(0.6) 27(2.2)
Type of TB 0.020
New smear-positive 548 (38.7) 484 (40.1)
New smear-negative 473 (33.4) 345 (28.6)
New EPTB 396 (27.9) 379 (31.4)
*All data are n (%).
PCT, patient centred treatment; EPTB, extra pulmonary tuberculosis.Page 5 of 10
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Table 2: Treatment outcomes.
Historic PCT RR† 95% CI P-value
Smear-positive patients n = 548* n = 484*
Smear conversion 409 (74.6) 388 (80.2) 1.07 1.01 -- 1.15 0.037
Cure 334 (60.9) 312 (64.5) 1.06 0.96 -- 1.16 0.247
Success 382 (69.7) 398 (82.2) 1.18 1.10 -- 1.26 <0.001
Death 92 (16.8) 59 (12.2) 0.73 0.54 -- 0.98 0.042
Default 28 (5.1) 13 (2.7) 0.53 0.28 -- 0.99 0.055
Transfer out 41 (7.5) 14 (2.9) 0.39 0.22 -- 0.68 0.001
Fail 2 (0.4) 0
Missing outcome 3 (0.6) 0
All patients n = 1417* n = 1208*
Success 1015 (71.6) 954 (79.0) 1.10 1.05 -- 1.15 <0.001
Death 249 (17.6) 168 (13.9) 0.79 0.66 -- 0.95 0.012
Default 61 (4.3) 40 (3.3) 0.77 0.52 -- 1.14 0.222
Transfer out 80 (5.7) 41 (3.4) 0.60 0.42 -- 0.86 0.007
Fail 2 (0.1) 0
Missing outcome 10 (0.7) 4 (0.3)
*All data are n (%).
† Relative risk comparing PCT cohort with historic cohort.
CI, confidence interval.
Table 3: Factors associated with cure smear-positive patients in patient centred treatment cohort.
Univariable Multivariable
OR 95% CI P OR 95% CI P
Treatment observation*
HF-DOT 1 1
HB-DOT 2.37 1.27 -- 4.43 0.007 2.31 1.22 -- 4.38 0.010
District
Kahama 1 1
Arusha 1.38 0.87 -- 2.20 0.169 1.27 0.79 -- 2.04 0.315




Female 1.19 0.75 -- 1.89 0.450
Relationship
Non-family member 1
Family member 1.09 0.46 -- 2.61 0.843
Age
< 25 years 1
25 -- 34 years 1.06 0.50 -- 2.24 0.879
35 -- 44 years 0.96 0.42 -- 2.15 0.912
>= 45 years 0.84 0.38 -- 1.85 0.670
Education
None 1
Primary education 1.74 0.92 -- 3.27 0.087
Above primary education 1.64 0.69 -- 3.89 0.258
* In all new smear-positive patients (n = 484)
† In HB-DOT group (n = 440)
HF, health facility; HB, home-based; DOT, directly observed treatment; CI, confidence interval; OR, odds ratio.
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health facility (RR: 2.37; 95% CI: 1.27 - 4.43; P = 0.007;
Table 3). This was seen in all districts, although the effect
was larger in Arusha than in Kahama and Mufindi which,
however, did not lead to a statistically significant effect
modification in any of the statistical models. Adjusting
the effect of home-based treatment for these differences in
districts did not change the results (RR: 2.31; 95% CI: 1.22
- 4.38; P = 0.010).
Treatment success in the entire PCT cohort was also more
likely to be reported by patients who choose home-based
treatment (RR: 4.19; 95% CI: 2.91 - 6.05; P < 0.001).
Again, the effect was larger in Arusha than in the other two
districts but did not lead to significant effect modification.
Adjustment did not alter the effect of home-based treat-
ment (RR: 4.11; 95% CI: 2.82 - 6.00; P < 0.001).
Effect of supporters on treatment outcomes
Of the supporters, 76% were family members (including
spouses), 5% were non-family members - for 19%, no
information on the relationship was available. None of
the supporter characteristics was associated either with
cure of smear-positive patients (Table 3) or treatment suc-
cess for any of the patients (Table 4). The cure and treat-
ment success rates in patients who had a family member
as a supporters were as high as patients who had a non-
family member as a supporter.
Discussion
This study showed that treatment outcomes in a cohort of
new TB patients receiving treatment under the PCT strat-
egy were comparable to treatment outcomes in patients
who received treatment with the conventional health
facility-based DOT and administration of loose drugs. The
higher success rate in the PCT cohort is driven by a larger
proportion of patients completing their treatment. This
finding is not easy to interpret. It might be just an effect
caused by the fact that the treatment was for 2 months
less. For the verifiable outcome cure, there is no difference
between the historical cohort and the PCT cohort. In addi-
tion, the study did not identify any supporter characteris-
tic that influenced the achievement of cure or treatment
success in patients who had their treatment observed at
home.
These findings are in line with the results from other stud-
ies performed in a variety of settings. A cluster-rand-
omized trial in Nepal showed that 89% of the patients
who had their treatment intake observed by a family
member had a treatment success. This was comparable
with the 85% success in patients who were supervised by
Table 4: Factors associated with success all patients in patient centred treatment cohort.
Univariable Multivariable
OR 95% CI P OR 95% CI P
Treatment observation*
HF-DOT 1 1
HB-DOT 4.19 2.91 -- 6.05 < 0.001 4.11 2.82 -- 6.00 < 0.001
District
Kahama 1 1
Arusha 0.52 0.37 -- 0.74 <0.001 1.64 1.15 -- 2.33 0.006




Female 0.99 0.67 -- 1.47 0.974
Relationship
Non-family member 1
Family member 1.05 0.46 -- 2.39 0.910
Age
< 25 years 1
25 -- 34 years 0.70 0.35 -- 1.43 0.332
35 -- 44 years 0.92 0.43 -- 1.98 0.845
>= 45 years 0.50 0.25 -- 1.05 0.067
Education
None 1
Primary education 1.61 0.92 -- 2.85 0.098
Above primary education 0.97 0.49 -- 1.96 0.950
* In all new patients (n = 1208)
† In HB-DOT group (n = 1066)
OR, odds ratio; CI, confidence interval; HF, heath facility; HB, home-based.Page 7 of 10
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ment targets from the WHO (85%) [17]. A retrospective
study in Thailand assessed treatment outcomes in patients
who accepted direct observation of treatment by staff of
the health facility, a village health worker or a family
member. Ninety percent of the patients opted for observa-
tion by a family member and 10% for the health staff of
the facility. Only one of the 216 patients chose observa-
tion by a village health worker. The success rate was higher
in patients observed by a family member (87%) com-
pared to patients observed by health staff (76%) [15]. A
randomized trial in Swaziland reported that treatment
observation by family members obtained similar success
rates in TB patients as did treatment observation by com-
munity health workers (66% and 68%, respectively) [18].
Similarly, a randomized trial in Pakistan did not find any
differences in treatment success rates in patients observed
by family members (62%), observation at the health facil-
ity (67%) or self-administration (62%) [19].
Despite these findings, the ultimate proof of principle for
the efficacy of home-based treatment observation is not
given by the short-term cure rates or success rate as
assessed in this and other studies. Only when, in settings
with home-based DOT, the relapse rates do not increase
(and preferentially decrease due to improved adherence)
can home-based DOT be regarded as effective.
The concept of treatment observation by family members
is still controversial within the TB community. The WHO
treatment guidelines state that family members should, in
general, not be considered as treatment supporters [3].
However, in the updated guidelines on community
involvement in TB care, there is a shift towards the idea
that there is a need to provide 'an increased range of treat-
ment support options', although this statement was
mainly geared at TB patients co-infected with HIV [20].
Despite the above mentioned results of the PCT approach,
the success rate in Tanzania remains below the 85% target
set by WHO. This relatively low success rate is mainly
driven by the death rate. It is more than likely that this rate
is largely a result of co-infection with HIV. It is known that
HIV-associated death in TB patients is generally seen at the
start of TB-treatment. Even the PCT approach will not
have a major impact on these events, which is reflected in
a death rate of 12%.
There are several arguments formulated by those who are
against the use of family members as treatment support-
ers. First, family members are not always able to be firm
on treatment intake, especially if the patient suffers side
effects or if the social context makes it difficult or inappro-
priate to do so [21]. Second, the design of most studies
showing similar, or better, treatment outcomes with
observation by family members than by health workers
actually test multifaceted interventions including
increased monitoring, supervision and training. In the
Nepal study, there were frequent visits to the households
by research staff in order to monitor the implementation
and to collect data. In Thailand, clinic staff were strongly
involved in the identification of a treatment supporter
and special boxes were prepared in order to facilitate treat-
ment delivery at home [15]. In Senegal, the intervention
was clearly multifaceted, including improved communi-
cation between health staff and patients and increased
training and supervision, making it impossible to tease
out the effect of decentralized treatment observation [22].
Third, treatment observation outside the health facility is,
in practise, more frequently self administration of treat-
ment. This was shown in a study by a study in Thailand
where 11% of the health personnel did not perform any
treatment observation, compared to 23% of community
members and 35% of family members [23].
The major limitation of the study was the change in
design which meant that the present study was not able to
adequately test the independent effect of the type of treat-
ment delivery. Instead, it tested a multifaceted interven-
tion. Each part of this intervention might have
contributed to the positive findings. In the PCT cohort, all
drugs were taken as FDC during the full treatment period.
In the control cohort, FDC was only available for isoni-
azid and rifampicin during the intensive phase. All other
drugs were administered as loose drugs. Drug delivery by
FDCs might be associated with an improved adherence to
therapy [24]. At the same time, the treatment regimen was
changed to include rifampicin throughout the duration.
An additional 4 months of this potent drug might posi-
tively influence the cure rate in the PCT cohort. However,
the additional efficacy of this treatment regimen over the
conventional regimen used in the control cohort is based
largely on the relapse rates and not on the initial cure
rates. If the new regimen had an effect on the outcome it
was most likely due to its shorter duration and, therefore,
the possible higher completion rates, rather than an
increased drug efficacy. However, the total intervention
will be rolled-out in the rest of the country making the
individual contributions of the multifaceted intervention
towards the overall positive effect less important. The
important finding, that the type of treatment supporter
does not influence treatment outcome, makes this nation-
wide scale-up of the intervention more feasible.
Another limitation was the absence of demographic infor-
mation for a considerable number of treatment support-
ers. As mentioned, this did not introduce a bias because of
the concurrent start of the study in the districts and the
retaining of the freedom of choice for the type of treat-
ment delivery strategy. There is also a marked absence ofPage 8 of 10
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study (2005 for the historical cohort and 2006 of the PCT
cohort), routine HIV testing for newly registered patients
had not been fully implemented. Collection of this infor-
mation for inclusion in statistical models would lead to a
bias, given the large proportion of patients who would not
have this information. A comparison of this information
between the two cohorts would also be not possible due
to the increase in routine testing between 2005 and 2006.
There is some indication that ascertainment bias might
have influenced the results in Arusha. In this district case
notification increased considerably during the study and
there was, also, a significantly higher probability of cure in
the PCT cohort. This may indicate improved diagnosis
and/or microscopy. It could also be a result of the quality
control measures that were imposed in the PCT cohort but
not the historical cohort. However, adjusting the multi-
variable models did not give any change in the point esti-
mates or the confidence intervals, making this potential
bias of little value.
Acceptable and feasible treatment observation strategies
are highly context specific [25]. In Tanzania, home-based
treatment observation by a supporter of choice is widely
appreciated and does not lead to an increase in unfavour-
able treatment outcomes compared to conventional treat-
ment delivery strategies. It allows patients to rest and
recover, as daily health facility DOT places considerable
physical strain on patients. Being at home also made it
possible for the patient to engage in productive activities
and reduce the cost of travel associated with the daily
health facility visits. At the same time, it could ease the
burden on health facilities [2]. Studies from Malawi and
Australia have shown that, in a decentralized setting,
adherence to treatment can be as high as seen in health-
facility based treatment observation [16,26]. However, it
is important to assess adherence to treatment in the set-
ting of Tanzania.
The programmatic condition in which this study was car-
ried out lends strong support to the scaling up of the PCT
strategy in Tanzania. This must coincide with rigorous
supervision of the health facilities implementing the strat-
egy. Furthermore, follow-up of this first cohort of patients
treated under the PCT strategy will give much needed data
on the risk of relapse and the resistance patterns in patient
who need retreatment: two factors that determine the
long-term efficacy of the intervention.
The positive effect of home-based treatment in a program-
matic setting found in this study can be of value for areas
outside the context of TB. HIV-programmes in especially
resource-poor areas are experimenting with such an
approach [27,28]. The findings that home-based treat-
ment can be achieved under programmatic conditions
might give the much needed impetus to move from
smaller projects to a more general implementation within
national treatment programmes.
Conclusions
The PCT approach showed similar cure rates and better
treatment success rates compared to daily health-facility
DOT. The results indicate that there are no specific prereq-
uisites for the supporter chosen by the patient. The pro-
grammatic setting of the study lends strong support for
scaling-up of TB treatment observation outside the health
facility.
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